Evidence map›Paper›PMID 30215228›Full record

ArticleAnnals of laboratory medicine2019

Molecular Epidemiology and Mechanisms of 43 Low-Level Linezolid-Resistant

Ruoyi Hua, Yun Xia, Wenyao Wu, Mi Yang, Jia Yan

Open access · diamondAbstract read
In one paragraph

Article in Annals of laboratory medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Antimicrobial agents and chemotherapy · 2025
    Article
  3. Article
  4. Article
  5. Emergence ofInfection and drug resistance · 2022
    Article
  6. Prevalence and Characteristics of Phenicol-Oxazolidinone Resistance Genes inInternational journal of molecular sciences · 2021
    Article
  7. Review
  8. Article
  9. Emergence ofAnnals of laboratory medicine · 2020
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ruoyi HuaDepartment of Clinical Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yun XiaDepartment of Clinical Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. xiayun12cn@aliyun.com.ORCID https://orcid.org/0000-0003-3136-8548
Wenyao WuDepartment of Clinical Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Mi YangDepartment of Clinical Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jia YanDepartment of Clinical Laboratory, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
The Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

National Natural Science Foundation of China 81572055
6 · The paper itself

Abstract

background

methodsA total of 1,120 non-duplicated

resultsAll 43 low-level LRE strains (minimum inhibitory concentration: 8-16 mg/L) harbored

conclusions

Indexed as

Anti-Bacterial AgentsBacterial ProteinsChinaDrug Resistance, BacterialElectrophoresis, Gel, Pulsed-FieldEnterococcus faecalisGram-Positive Bacterial InfectionsHumansLinezolidMicrobial Sensitivity TestsMultilocus Sequence TypingRibosomal Protein L3Ribosomal ProteinsRNA, Ribosomal, 23SSequence Analysis, DNAAnti-Bacterial AgentsBacterial ProteinsLinezolidRibosomal Protein L3ribosomal protein L4Ribosomal ProteinsRNA, Ribosomal, 23SEnterococcusEpidemiologyLinezolidMechanismResistance

Identifiers

PMID30215228
PMCPMC6143467
OpenAlexW2891155361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.